Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 18/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.49 |
| ▸ | LCK | P06239 | 1/20 | 0.49 |
| ▸ | CSF1R | P07333 | 1/20 | 0.49 |
| ▸ | KDR | P35968 | 1/20 | 0.49 |
| ▸ | HSPB1 | P04792 | 1/20 | 0.49 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.49 |
| ▸ | RAF1 | P04049 | 1/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | SGK1 | O00141 | 1/20 | 0.47 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4494520 | 1.00 | MAPK14 (0.53) | MAPK14CYP2C9LCKCSF1RKDR | |
| SCHEMBL4512693 | 0.88 | MAPK14 (0.50) | MAPK14CYP2C9LCKCSF1RKDR | |
| SCHEMBL4502955 | 0.81 | MAPK14 (0.58) | MAPK14CYP2C9LCKCSF1RKDR | |
| SCHEMBL4502790 | 0.80 | MAPK14 (0.59) | MAPK14CYP2C9LCKCSF1RKDR | |
| SCHEMBL4503641 | 0.80 | MAPK14 (0.53) | MAPK14CYP2C9LCKCSF1RKDR | |
| SCHEMBL4493100 | 0.79 | MAPK14 (0.53) | MAPK14CYP2C9LCKCSF1RKDR | |
| SCHEMBL4514200 | 0.78 | MAPK14 (0.61) | MAPK14CYP2C9LCKCSF1RKDR | |
| SCHEMBL4511781 | 0.77 | MAPK14 (0.51) | MAPK14CYP2C9LCKCSF1RKDR | |
| SCHEMBL4501453 | 0.77 | MAPK14 (0.53) | MAPK14CYP2C9LCKCSF1RKDR | |
| SCHEMBL4506822 | 0.77 | MAPK14 (0.50) | MAPK14CYP2C9LCKCSF1RKDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090286775-A1 | Bicyclic Derivatives as P38 Kinase Inhibitors | PALAU PHARMA, S.A. (ES) | 2009-11-19 | — | — | US | claimed |
| US-20090286775-A1 | Bicyclic Derivatives as P38 Kinase Inhibitors | PALAU PHARMA, S.A. (ES) | 2009-11-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090286775-A1 | Bicyclic Derivatives as P38 Kinase Inhibitors | MAPK1, MAPKAPK2, MAPKAPK3 | MAPK14 26/4885CYP2C9 3389/4885LCK 173/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.